EUVIMEDEUVIMED entdecken
Open Access

Clinical, Biochemical, and Genetic Profile of an Indian Kindred with Type 1 Familial Hypocalciuric Hypercalcemia

Sarah Alam, Alpesh Goyal, Nikhil Tandon

Indian Journal of Endocrinology and Metabolism · 2021-09 · 25 (5) · 462-465

DOI: 10.4103/ijem.ijem_349_21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Endocrinology and Metabolism, online erschienen am 12.01.2022. Verfasst von Sarah Alam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sir, Familial hypocalciuric hypercalcemia (FHH) is a rare genetic disorder with autosomal dominant inheritance and high penetrance that manifests with mild parathyroid hormone (PTH)-dependent hypercalcemia and hypocalciuria.[12] The disorder results from an inherited defect in calcium sensing mechanism at the level of parathyroid gland and the thick ascending limb of loop of Henle of kidney.[3] FHH is genetically heterogenous and three subtypes have been described, namely, FHH1, FHH2, and FHH3, related to inactivating mutations in the genes encoding calcium sensing receptor (CaSR), G-protein subunit alpha-11 (GNA11), and adaptor-related protein complex 2 sigma 1 subunit (AP2S1) proteins, respectively.[3] Most patients with FHH are asymptomatic.[4] The disorder runs a benign course in most patients; parathyroidectomy is neither required, nor it is curative.[5] Symptoms of neonatal hypocalcemia have been described in unaffected children of women affected with this rare disorder.[6] Here, we describe an Indian kindred with genetically confirmed type 1 FHH where the presentation in the index case was delayed till the age of 48 years, and confounded by secondary hyperparathyroidism related to vitamin D deficiency. A 48-year-old female initially presented to an orthopedic specialist with complaints of generalized body ache for the past 2 years. Her initial work-up including complete blood count, liver and kidney function tests was unremarkable. She had mild hypercalcemia (serum calcium: 10.8 mg/dL, N: 8.5-10.5 mg/dL), mild hypophosphatemia (serum phosphate: 2.4 mg/dL, N: 2.5-4.5 mg/dL), raised serum PTH (164.7 pg/mL, N: 15-65 pg/mL), and low serum 25-hydroxyvitamin D levels (6.8 ng/mL, N: 20-50 ng/mL) [Table 1]. A further work-up of hypercalcemia was not done and the patient was administered calcium (1 gram per day elemental calcium) and injectable (cholecalciferol 600,000 IU intramuscular once a week for 2 weeks), followed by oral vitamin D (cholecalciferol 60,000 IU sachet once a week for 8 weeks) preparations. On a follow-up visit, serum PTH levels reduced to 102 pg/mL; however, hypercalcemia persisted [Table 1]. Thereafter, she was referred to our department for evaluation. On revisiting the history, she had no complaints other than the generalized body ache. She denied history of nausea, vomiting, fragility fractures, neuropsychiatric manifestations, and intake of lithium or any other drugs known to cause hypercalcemia. Her symptom of body ache improved significantly after vitamin D supplementation. She was premenopausal and had regular menses. She had a history of renal colic 12 years back when she was detected to have bilateral renal micro-concretions without any definite calculus and advised adequate fluid intake. No metabolic work-up was done at that time, and there was no recurrence of abdominal pain following the initial episode. She had two children, 14 and 20 years of age, who had normal birth and development history. There was no family history of hypercalcemia or failed parathyroid surgery in any relative. Her height, weight, and body mass index (BMI) were 168 cm, 61 kg, and 21.6 kg/m2, respectively. There were no features to suggest multiple endocrine neoplasia (MEN) syndrome. Rest of her general and systemic examination was unremarkable.Table 1: Biochemical profile of the index patient and her childrenWe repeated her biochemical investigations. Serum and urine calcium were measured using ortho-cresolphtalein complexone (o-CPC) method on Modular P800 Clinical Chemistry autoanalyser (Roche Diagnostics, Germany). Albumin-adjusted or “corrected” calcium is known to underestimate calcium status in patients with increased serum albumin[7]; therefore, we have not reported “corrected” serum calcium values in this paper. Serum and urine creatinine were measured using kinetic Jaffe method on the same autoanalyser. Serum PTH was measured using an electrochemiluminescent immunoassay on cobas e-411 autoanalyser (Roche Diagnostics, Germany) and serum 25(OH) D was measured using a chemiluminescent immunoassay on Liaison XL autoanalyser (DiaSorin Inc., USA). Urine calcium creatinine clearance ratio (CCCR) was calculated as: [24-hour urine calcium × serum creatinine] ÷ [24-hour urine creatinine × serum calcium]. A urine CCCR of T; c.413C>T; Depth 83x)) that resulted in amino acid substitution of methionine for threonine at codon 138 (p. Thr138Met). The CASR gene has multiple pseudogenes in the human genome. Therefore, further validation of NGS result was performed using Sanger sequencing (Medgenome Laboratories, Bangalore, India), which confirmed the variant in the index patient, and subsequently, both her children [Figure 1]. We searched for published variants in literature and this variant has been previously described.[910] A diagnosis of FHH type 1 was therefore confirmed and the family was counselled about the benign nature of this condition.Figure 1: Sequence chromatogram and the reference sequence showing the variation in exon 3 of the CASR gene (chr3:121976155C>T; c.413C>T, p. Thr138Met) detected in heterozygous condition by Sanger sequencing in the index case and her childrenEstimation of serum PTH levels is an important initial step in broad subtyping of hypercalcemia into PTH-dependent and PTH-independent cause. Primary hyperparathyroidism (PHPT) is by far the most common cause of PTH-dependent hypercalcemia, with prevalence estimates of 1–4 cases per 1,000 adults.[11] On the other hand, FHH is a rare but important cause of PTH-dependent hypercalcemia, the prevalence of which has been reported at 1 in 78,000.[12] FHH is characterized by mild hypercalcemia (usually 0.02; however, about 20% patients with PHPT, especially those with co-existing vitamin D deficiency may manifest with a low urine CCCR of

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.

Zitieren

APA

Alam, S., Goyal, A., & Tandon, N. (2021). Clinical, Biochemical, and Genetic Profile of an Indian Kindred with Type 1 Familial Hypocalciuric Hypercalcemia. Indian Journal of Endocrinology and Metabolism, 25(5), 462-465. https://doi.org/10.4103/ijem.ijem_349_21

Vancouver

Alam S, Goyal A, Tandon N. Clinical, Biochemical, and Genetic Profile of an Indian Kindred with Type 1 Familial Hypocalciuric Hypercalcemia. Indian Journal of Endocrinology and Metabolism. 2021;25(5):462-465. doi:10.4103/ijem.ijem_349_21

BibTeX
@article{Alam2021,
  author = {Alam, Sarah and Goyal, Alpesh and Tandon, Nikhil},
  title = {Clinical, Biochemical, and Genetic Profile of an Indian Kindred with Type 1 Familial Hypocalciuric Hypercalcemia},
  journal = {Indian Journal of Endocrinology and Metabolism},
  year = {2021},
  volume = {25},
  number = {5},
  pages = {462--465},
  doi = {10.4103/ijem.ijem_349_21}
}
Kostenlos starten →